[Numerical taxonomy: methods and present development].

R. Sokal

Abstract:

What problem does this paper attempt to address?

Situation of snakebite, antivenom market and access to antivenoms in ASEAN countries

Chanthawat Patikorn,Ahmad Khaldun Ismail,Syafiq Asnawi Zainal Abidin,Francis Bonn Blanco,Jörg Blessmann,Khamla Choumlivong,John David Comandante,Uyen Vy Doan,Zainalabidin Mohamed @ Ismail,Yi Yi Khine,Tri Maharani,Myat Thet Nwe,Reza Murad Qamruddin,Ruth Sabrina Safferi,Emelia Santamaria,Patrick Joseph G Tiglao,Satariya Trakulsrichai,Taksa Vasaruchapong,Nathorn Chaiyakunapruk,Suthira Taychakhoonavudh,Iekhsan Othman

DOI: https://doi.org/10.1136/bmjgh-2021-007639

IF: 8.056

2022-03-01

BMJ Global Health

Abstract:Introduction Snakebite envenoming is a neglected tropical disease posing public health challenges globally. The Association of Southeast Asian Nations (ASEAN) countries are among the tropical regions with disproportionately high incidence of snakebite. Hence, this study aimed to review the situation of snakebite, antivenom market and access to antivenoms in ASEAN. Methods This mixed-methods study included comprehensive literature review and in-depth interviews with key informants to assess the situation of management system of snakebite, antivenom market and access to antivenoms in seven ASEAN countries, including Malaysia, Thailand, Indonesia, Philippines, Vietnam, Lao PDR and Myanmar. Data were analysed by a framework method. Results ASEAN have developed various strategies to improve outcomes of snakebite victims. Five domestic antivenom manufacturers in the region produce up to 288 375 vials of antivenoms annually with the value of US$13 058 053 million which could treat 42 213 snakebite victims. However, there remain challenges to be addressed especially the lack of snakebite-related informatics system, inadequate antivenoms at the healthcare facilities and when the majority of snakebite victims seek traditional healers instead of conventional treatment. Conclusion Improving the situation of snakebite and antivenom is not only about the availability of antivenom, but the whole landscape of surrounding management and supporting system. The assessment of the situation of snakebite and antivenom is crucial for countries or regions where snakebites are prevalent to recognise their current standpoint to inform the development of strategies to achieve the goal set by the WHO of halving the global burden of snakebite by 2030.

public, environmental & occupational health
Consequences of neglect: analysis of the sub-Saharan African snake antivenom market and the global context

Nicholas I Brown

DOI: https://doi.org/10.1371/journal.pntd.0001670

Abstract:Background: The worldwide neglect of immunotherapeutic products for the treatment of snakebite has resulted in a critical paucity of effective, safe and affordable therapy in many Third World countries, particularly in Africa. Snakebite ranks high among the most neglected global health problems, with thousands of untreated victims dying or becoming permanently maimed in developing countries each year because of a lack of antivenom-a treatment that is widely available in most developed countries. This paper analyses the current status of antivenom production for sub-Saharan African countries and provides a snapshot of the global situation. Methods: A global survey of snake antivenom products was undertaken in 2007, involving 46 current and former antivenom manufacturers. Companies producing antivenom for use in sub-Saharan Africa were re-surveyed in 2010 and 2011. Results: The amount of antivenom manufactured for sub-Saharan Africa increased between 2007 and 2010/11, however output and procurement remained far below that required to treat the estimated 300,000-500,000 snakebite victims each year. Variable potency and inappropriate marketing of some antivenoms mean that the number of effective treatments available may be as low as 2.5% of projected needs. Five companies currently market antivenom for sale in Africa; three others have products in the final stages of development; and since 2007 one has ceased production indefinitely. Most current antivenom producers possess a willingness and capacity to raise output. However inconsistent market demand, unpredictable financial investment and inadequate quality control discourage further production and threaten the viability of the antivenom industry. Conclusion: Financial stimulus is urgently needed to identify and develop dependable sources of high-grade antivenoms, support current and emerging manufacturers, and capitalise on existing unutilised production capacity. Investing to ensure a consistent and sustainable marketplace for efficacious antivenom products will drive improvements in quality, output and availability, and save thousands of lives each year.
Progress and Challenges in the Field of Snakebite Envenoming Therapeutics

José María Gutiérrez,Nicholas R. Casewell,Andreas H. Laustsen

DOI: https://doi.org/10.1146/annurev-pharmtox-022024-033544

2024-08-01

Abstract:Snakebite envenoming kills and maims hundreds of thousands of people every year, especially in the rural settings of tropical regions. Envenomings are still treated with animal-derived antivenoms, which have prevented many lives from being lost but which are also medicines in need of innovation. Strides are being made to improve envenoming therapies, with promising efforts made toward optimizing manufacturing and quality aspects of existing antivenoms, accelerating research and development of recombinant antivenoms based on monoclonal antibodies, and repurposing of small-molecule inhibitors that block key toxins. Here, we review the most recent advances in these fields and discuss therapeutic opportunities and limitations for different snakebite treatment modalities. Finally, we discuss challenges related to preclinical and clinical evaluation, regulatory pathways, large-scale manufacture, and distribution and access that need to be addressed to fulfill the goals of the World Health Organization's global strategy to prevent and control snakebite envenoming.

pharmacology & pharmacy,toxicology
Clinical management of snakebite envenoming: Future perspectives

Muhammad Hamza,Cecilie Knudsen,Christeine Ariaranee Gnanathasan,Wuelton Monteiro,Matthew R Lewin,Andreas H Laustsen,Abdulrazaq G Habib

DOI: https://doi.org/10.1016/j.toxcx.2021.100079

2021-08-08

Toxicon X

Abstract:Snakebite envenoming is a major cause of morbidity and mortality in rural communities throughout the tropics. Generally, the main clinical features of snakebites are local swelling, tissue necrosis, shock, spontaneous systemic hemorrhage, incoagulable blood, paralysis, rhabdomyolysis, and acute kidney injury. These clinical manifestations result from complex biochemical venom constituents comprising of cytotoxins, hemotoxins, neurotoxins, myotoxins, and other substances. Timely diagnosis of envenoming and identification of the responsible snake species is clinically challenging in many parts of the world and necessitates prompt and thorough clinical assessment, which could be supported by the development of reliable, affordable, widely-accessible, point-of-care tests. Conventional antivenoms based on polyclonal antibodies derived from animals remain the mainstay of therapy along with supportive medical and surgical care. However, while antivenoms save countless lives, they are associated with adverse reactions, limited potency, and are relatively inefficacious against presynaptic neurotoxicity and in preventing necrosis. Nevertheless, major scientific and technological advances are facilitating the development of new molecular and immunologic diagnostic tests, as well as a new generation of antivenoms comprising human monoclonal antibodies with broader and more potent neutralization capacity and less immunogenicity. Repurposed pharmaceuticals based on small molecule inhibitors (e.g., marimastat and varespladib) used alone and in combination against enzymatic toxins, such as metalloproteases and phospholipase A2s, have shown promise in animal studies. These orally bioavailable molecules could serve as early interventions in the out-of-hospital setting if confirmed to be safe and efficacious in clinical studies. Antivenom access can be improved by the usage of drones and ensuring constant antivenom supply in remote endemic rural areas. Overall, the improvement of clinical management of snakebite envenoming requires sustained, coordinated, and multifaceted efforts involving basic and applied sciences, new technology, product development, effective clinical training, implementation of existing guidelines and therapeutic approaches, supported by improved supply of existing antivenoms.
Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?

Andreas H. Laustsen,Kristoffer H. Johansen,Mikael Engmark,Mikael R. Andersen

DOI: https://doi.org/10.1371/journal.pntd.0005361

2017-02-03

PLoS Neglected Tropical Diseases

Abstract:Snakebite envenoming is a major public health burden in tropical parts of the developing world. In sub-Saharan Africa, neglect has led to a scarcity of antivenoms threatening the lives and limbs of snakebite victims. Technological advances within antivenom are warranted, but should be evaluated not only on their possible therapeutic impact, but also on their cost-competitiveness. Recombinant antivenoms based on oligoclonal mixtures of human IgG antibodies produced by CHO cell cultivation may be the key to obtaining better snakebite envenoming therapies. Based on industry data, the cost of treatment for a snakebite envenoming with a recombinant antivenom is estimated to be in the range USD 60-250 for the Final Drug Product. One of the effective antivenoms (SAIMR Snake Polyvalent Antivenom from the South African Vaccine Producers) currently on the market has been reported to have a wholesale price of USD 640 per treatment for an average snakebite. Recombinant antivenoms may therefore in the future be a cost-competitive alternative to existing serum-based antivenoms.

tropical medicine,parasitology
Challenges associated with the availability, accessibility, and use of antivenoms for treating snakebite envenoming in Ghana: A MaxDiff experiment design

Eric Nyarko,Ebenezer Kwesi Ameho,Samuel Iddi,Louis Asiedu

DOI: https://doi.org/10.1016/j.toxicon.2023.107594

IF: 3.035

2024-01-07

Toxicon

Abstract:Successful snakebite envenoming (SBE) treatment requires safe, effective, and quality-assured antivenom products specifically tailored to combat endemic venomous snake species. This study aims to identify the challenges associated with the availability, accessibility, and use of antivenoms for treating SBE. The data for this study were obtained from a cross-sectional study involving healthcare workers from two districts (namely Afram Plains North and Afram Plains South) in the Eastern Region of Ghana. Through the MaxDiff design methodology, we quantify the challenges associated with the availability, accessibility, and use of antivenoms. Responses from a simple random sample of 203 healthcare workers were included in this study. Participants identified the high cost of antivenoms as the most challenging factor that limits the availability, accessibility, and use of antivenoms for treating SBE. Other important challenges were the lack of access to effective antivenoms in remote areas when needed and the increased use of unorthodox and harmful practices, followed by resort to unorthodox and harmful practices and the lack of effective antivenoms to address envenoming from local species in some instances. However, poor outcomes from using substandard antivenoms, stock-outs, inadequate number of manufacturers, and the resort to substandard, cheap, and harmful antivenoms were traded off. Also, poor utilization of antivenoms, suboptimal utilization of antivenoms (low quality, under-dose), use of ineffective, substandard antivenoms, and flooding of the market with products that have not been evaluated thoroughly were underscored. Our findings provide essential data to guide discussions on barriers to the availability, accessibility, and use of antivenoms for treating SBE to improve the supply of antivenoms, enhance the effectiveness of snakebite treatment, and improve patient care quality in Ghana. Multi-component strategies are needed to address the challenges identified, such as intensified advocacy, ongoing education and community engagement, healthcare worker training, and leveraging institutional and governance structures.

pharmacology & pharmacy,toxicology
Therapeutic itineraries of snakebite victims and antivenom access in southern Mexico

Chloe Vasquez,Edgar Neri Castro,Eric D Carter

DOI: https://doi.org/10.1371/journal.pntd.0012301

2024-07-05

Abstract:Access to antivenoms in cases of snakebite continues to be an important public health issue around the world, especially in rural areas with poorly developed health care systems. This study aims to evaluate therapeutic itineraries and antivenom accessibility following snakebites in the states of Oaxaca and Chiapas in southern Mexico. Employing an intercultural health approach that seeks to understand and bridge allopathic and traditional medical perceptions and practices, we conducted field interviews with 47 snakebite victims, documenting the therapeutic itineraries of 54 separate snakebite incidents that occurred between 1977 and 2023. Most victims used traditional remedies as a first line of treatment, often to withstand the rigors of a long journey to find antivenoms. The main obstacles to antivenom access were distance, poor antivenom availability, and cost. Standard antivenom treatment is highly valued and sought after, even as traditional beliefs and practices persist within a cultural framework known as the "hot-cold" system. The findings are crucial for informing future enhancements to antivenom distribution systems, health education initiatives, and other interventions aimed at mitigating the impact of snakebites in the region.
Beyond the 'big four': Venom profiling of the medically important yet neglected Indian snakes reveals disturbing antivenom deficiencies

R R Senji Laxme,Suyog Khochare,Hugo Francisco de Souza,Bharat Ahuja,Vivek Suranse,Gerard Martin,Romulus Whitaker,Kartik Sunagar

DOI: https://doi.org/10.1371/journal.pntd.0007899

2019-12-05

Abstract:Background: Snakebite in India causes the highest annual rates of death (46,000) and disability (140,000) than any other country. Antivenom is the mainstay treatment of snakebite, whose manufacturing protocols, in essence, have remained unchanged for over a century. In India, a polyvalent antivenom is produced for the treatment of envenomations from the so called 'big four' snakes: the spectacled cobra (Naja naja), common krait (Bungarus caeruleus), Russell's viper (Daboia russelii), and saw-scaled viper (Echis carinatus). In addition to the 'big four', India is abode to many other species of venomous snakes that have the potential to inflict severe clinical or, even, lethal envenomations in their human bite victims. Unfortunately, specific antivenoms are not produced against these species and, instead, the 'big four' antivenom is routinely used for the treatment. Methods: We characterized the venom compositions, biochemical and pharmacological activities and toxicity profiles (mouse model) of the major neglected yet medically important Indian snakes (E. c. sochureki, B. sindanus, B. fasciatus, and two populations of N. kaouthia) and their closest 'big four' congeners. By performing WHO recommended in vitro and in vivo preclinical assays, we evaluated the efficiencies of the commercially marketed Indian antivenoms in recognizing venoms and neutralizing envenomations by these neglected species. Findings: As a consequence of dissimilar ecologies and diet, the medically important snakes investigated exhibited dramatic inter- and intraspecific differences in their venom profiles. Currently marketed antivenoms were found to exhibit poor dose efficacy and venom recognition potential against the 'neglected many'. Premium Serums antivenom failed to neutralise bites from many of the neglected species and one of the 'big four' snakes (North Indian population of B. caeruleus). Conclusions: This study unravels disturbing deficiencies in dose efficacy and neutralisation capabilities of the currently marketed Indian antivenoms, and emphasises the pressing need to develop region-specific snakebite therapy for the 'neglected many'.
Snakebite Management: The Need of Reassessment, International Relations, and Effective Economic Measures to Reduce the Considerable SBE Burden

Rathore, Anurag S.

DOI: https://doi.org/10.1007/s44197-024-00247-z

2024-06-11

Journal of Epidemiology and Global Health

Abstract:The sole treatment for snakebite envenomation (SBE), the anti-snake venom (ASV), suffers from considerable drawbacks, including side effects and limited species specificity. Additionally, despite its existence for more than a century, uniform availability of good quality ASV does not yet exist. The present review describes the journey of a SBE victim and highlights the global crisis of SBE management. A detailed analysis of the current ASV market has also been presented along with the worldwide snake distribution. The current production of country specific licensed ASV throughout the globe along with their manufacturers has been examined at the snake species level. Furthermore, a detailed analysis of on-ground situation of SBE management in antivenom manufacturing countries has been done using the most recent literature. Additionally, the export and import of different ASVs have been discussed in terms of procurement policies of individual countries, their shortcomings, along with the possible solution at the species level. It is interesting to note that in most countries, the existence of ASV is really either neglected or overstated, implying that it is there but unsuitable for use, or that it is not present but can be obtained from other countries. This highlights the urgent need of significant reassessment and international collaborations not just for development and production, but also for procurement, distribution, availability, and awareness. A PROMISE (Practical ROutes for Managing Indigenous Snakebite Envenoming) approach has also been introduced, offering simple, economical, and easy to adopt steps to efficiently alleviate the worldwide SBE burden.

public, environmental & occupational health
From fangs to antidotes: A scoping review on snakebite burden, species, and antivenoms in the Eastern Mediterranean Region

Ali Alshalah,David J Williams,Alessandra Ferrario

DOI: https://doi.org/10.1371/journal.pntd.0012200

2024-07-31

Abstract:Background: Snake bites cause considerable morbidity and mortality worldwide, yet evidence from low- and middle-income countries remains fragmented. This is particularly the case in Eastern Mediterranean Region where available data on snake bites is relatively weak. Without reliable data, it is difficult to make the case for greater visibility and investment to address the snakebite burden in this Region. A scoping review was therefore conducted to summarize evidence on snake bites in countries of the Eastern Mediterranean. Methodology/principal findings: The review employed manual and electronic searching methods of four databases plus Google Scholar, ultimately including 196 records from 20 countries published between 2000 and 2023. More than half originated from Iran, Morocco, and Pakistan. Many records lacked information on permanent sequalae, disability, snake species, and types and sources of antivenoms. When identified, offending snakes belonged to 30 species. Use of more than 12 types of antivenoms were described across the Region, and some were not specific to indigenous species. Conclusion/significance: Despite the relatively large number of publications identified, the data were concentrated in just a few countries in the Region, and there was little or no information available for the remainder. As is the case worldwide, disability associated with snake bites was poorly characterized and quantified across the Region. There is an urgent need for concrete action at national and regional levels to enhance epidemiological surveillance, research, and the collection of clinical, disability and outcomes data to inform policy and public health investment. Greater regional cooperation and collaboration is also crucial for addressing this neglected disease throughout the Region.
LED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivation.

J. Castillo,J. Hung,M. Rodríguez,E. Bastidas,I. Laboren,A. Jaimes

DOI: https://doi.org/10.1016/J.AB.2005.05.027

IF: 2.9

2005-08-15

Analytical Biochemistry

Abstract:
Landscape of toxin-neutralizing therapeutics for snakebite envenoming (2015–2022): Setting the stage for an R&D agenda

Juliette Borri,José María Gutiérrez,Cecilie Knudsen,Abdulrazaq G. Habib,Maya Goldstein,Andrew Tuttle

DOI: https://doi.org/10.1371/journal.pntd.0012052

2024-03-27

PLoS Neglected Tropical Diseases

Abstract:Progress in snakebite envenoming (SBE) therapeutics has suffered from a critical lack of data on the research and development (R&D) landscape. A database characterising this information would be a powerful tool for coordinating and accelerating SBE R&D. To address this need, we aimed to identify and categorise all active investigational candidates in development for SBE and all available or marketed products. In this landscape study, publicly available data and literature were reviewed to canvas the state of the SBE therapeutics market and research pipeline by identifying, characterising, and validating all investigational drug and biologic candidates with direct action on snake venom toxins, and all products available or marketed from 2015 to 2022. We identified 127 marketed products and 196 candidates in the pipeline, describing a very homogenous market of similar but geographically bespoke products and a diverse but immature pipeline, as most investigational candidates are at an early stage of development, with only eight candidates in clinical development. Further investment and research is needed to address the shortfalls in products already on the market and to accelerate R&D for new therapeutics. This should be accompanied by efforts to converge on shared priorities and reshape the current SBE R&D ecosystem to ensure translation of innovation and access. Snakebite envenoming (SBE) is a neglected tropical disease that exerts a high impact worldwide, especially in sub-Saharan Africa, Asia, and Latin America. Animal-derived antivenoms constitute the only specific, scientifically validated treatment for envenomings, although new therapeutic alternatives are being pursued. Despite the relevance of this disease, there is a critical lack of data on the research and development landscape in antivenoms and novel therapeutics. This study describes a thorough search of the state of SBE therapeutic market and research pipeline. A total of 127 marketed products and 196 candidates were identified. The current antivenom landscape is characterised by a homogeneous market of similar but geographically bespoke products needing improvement. The R&D pipeline analysis component revealed a diverse but immature picture since only eight candidates are in clinical development. This article interprets the findings of the study to provide an initial list of priority areas that sets the stage for further development of an R&D agenda to ensure translation of innovation to reduce the impact of SBE.

tropical medicine,parasitology
Sexual behaviour and contraceptive use among socioeconomic groups of young women in the United States

K. Ford,M. Zelnik,J. Kantner

DOI: https://doi.org/10.1017/S0021932000013171

1981-01-01

Journal of Biosocial Science

Abstract:Summary Although much research has been devoted to understanding differences in contraceptive behaviour among socieconomic groups of married women, little is known about group differences among young unmarried women. In this paper, data from a national survey of women 15–19 years of age are used to study the relationship between socioeconomic status, sexual activity, and contraceptive use. The socioeconomic status of the young women is related to age at first intercourse, contraceptive use at first intercourse, regularity of use, and use of medical methods. The results indicate that both an earlier initiation of sexual activity and less regular use of contraceptives in all probability lead to a concentration of pregnancies in the lower socioeconomic groups.
Shortcomings in snake bite management in rural Cameroon: a case report

Frank-Leonel Tianyi,Christian Akem Dimala,Vitalis Fambombi Feteh

DOI: https://doi.org/10.1186/s13104-017-2518-8

2017-06-08

BMC Research Notes

Abstract:BackgroundSnake bites are an important public health problem in developing countries with most bites occurring in rural areas. Severe envenomation often occurs in children and following bites to the face. Prompt administration of potent anti-venom remains the mainstay of management. However in Cameroon, the use of anti-venoms is limited by non-availability, high cost (where available) and poor mastery of treatment guidelines.Case presentationWe present a 10-year-old muslim Cameroonian child from an enclaved rural area, brought to the hospital 12 h after a snake bite to the face, with signs of severe envenomation. Despite the suboptimal anti-venom dose administered to this patient due to a stock out of this medication, supportive therapy was beneficial in ensuring a positive outcome and satisfactory recovery.ConclusionThis highlights snake bites as a public health problem due to the lack of snake anti-venoms in peripheral health facilities, rendering them unable to appropriately manage these cases. National health policies should encourage constant peripheral availability of anti-venoms and the institution of an intervention package for snake bite management, comprising: treatment protocol, staff training, monitoring of compliance and community education to help reduce the mortality and morbidity from snake bites.
Harnessing the Cross-Neutralisation Potential of Existing Antivenoms for Mitigating the Outcomes of Snakebite in Sub-Saharan Africa

Suyog Khochare,Anurag Jaglan,U. Rashmi,Paulomi Dam,Kartik Sunagar

DOI: https://doi.org/10.3390/ijms25084213

IF: 5.6

2024-04-11

International Journal of Molecular Sciences

Abstract:Over 32,000 individuals succumb to snake envenoming in sub-Saharan Africa (sSA) annually. This results from several factors, including a lack of antivenom products capable of neutralising the venoms of diverse snake species in this region. Most manufacturers produce polyvalent antivenoms targeting 3 to 16 clinically important snake species in sSA. However, specific products are unavailable for many others, especially those with a restricted geographic distribution. While next-generation antivenoms, comprising a cocktail of broadly neutralising antibodies, may offer an effective solution to this problem, given the need for their clinical validation, recombinant antivenoms are far from being available to snakebite victims. One of the strategies that could immediately address this issue involves harnessing the cross-neutralisation potential of existing products. Therefore, we assessed the neutralisation potency of PANAF-Premium antivenom towards the venoms of 14 medically important snakes from 13 countries across sSA for which specific antivenom products are unavailable. Preclinical assays in a murine model of snake envenoming revealed that the venoms of most snake species under investigation were effectively neutralised by this antivenom. Thus, this finding highlights the potential use of PANAF-Premium antivenom in treating bites from diverse snakes across sSA and the utility of harnessing the cross-neutralisation potential of antivenoms.

biochemistry & molecular biology,chemistry, multidisciplinary
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment

Anna Carolina Machado Marinho,Alexander Chapeaurouge,Brunheld Maia Dutra,Barbara Cibelle S. F. Quintela,Soraya S. Pereira,Carla Freire C. Fernandes

DOI: https://doi.org/10.1016/j.drudis.2024.103967

IF: 8.369

2024-04-01

Drug Discovery Today

Abstract:Single-domain antibodies (sdAbs) hold promise for developing new biopharmaceuticals to treat neglected tropical diseases (NTDs), including snakebites, which are severe and occur frequently. In addition, limitations of conventional snakebite treatments, especially in terms of local action, and the global antivenom crisis incentivize the use of this biotechnological tool to design next-generation snakebite antivenoms. Conventional antivenoms for snakebite treatment are usually composed of...

pharmacology & pharmacy
Cobra Venom: From Envenomation Syndromes to Therapeutic Innovations

Ayoub Lafnoune,Asmaa Chbel,Bouchra Darkaoui,Imane Nait Irahal,Naoual Oukkache

DOI: https://doi.org/10.1007/s10989-024-10646-2

2024-10-06

International Journal of Peptide Research and Therapeutics

Abstract:Snakebite envenomation, classified as a neglected tropical disease, represents a significant global health threat, particularly in Asia and Africa, where it causes between 57,000 and 100,000 deaths annually. Envenomation by cobras, especially those of the genus Naja , contributes substantially to this burden. This review explores the complexities of cobra venom composition, its associated complications, and current treatment strategies, with a focus on venom-derived therapeutic prospects.

biochemistry & molecular biology
Snakebites and Antisnake Venom Utilization in Ghana's Oti Region: A 6-Year Retrospective Study

Courage Edem Ketor,Charles Kwaku Benneh,Kofi Boamah Mensah,Emmanuel Sarkodie,Adelaide Mensah,Samuel Owusu Somuah,Selorm Akakpo,Kwame Ohene Buabeng

DOI: https://doi.org/10.1155/2024/6692421

2024-08-06

Abstract:Background: Snakebite is a global environmental and occupational hazard and a significant public health threat. In rural areas, snakebite cases often go unreported and undocumented due to the lack of access to well-structured healthcare facilities/infrastructure. In some cases, the need for antisnake venom (ASV) far outstrips supply, negatively affecting treatment outcomes. This study, therefore, assessed the epidemiological characteristics of snakebite cases, their management, and how antivenoms are utilised at the selected hospital in the Jasikan District Hospital. Methods: A 6-year retrospective study using secondary data from antivenom return forms (pharmacy records), clinical records (patient folders), the District Health Information Management System-2 (DHIMS-2) database, and consulting room registers was carried out in selected hospitals in the Jasikan District, Oti, Ghana. Results: The predominant symptom of snakebite was localised pain (71.4%). The snakebite commonly occurred at home (19%) and on farms (18%). Of the 98 snakebite cases, ASV was administered to 73 (74.5%) cases. Supportive treatment applied included prophylactic antitetanus immunoglobulin (ATS) (80.6%), prophylactic antibiotics (63%), corticosteroids (80.6%), and analgesics (63%). 95% (n = 94) of complete recoveries were recorded; three were discharged against medical advice, and one was mortality. The supply and use of antivenom were erratic throughout the months of high incidence, partly due to inconsistent availability at the Regional Medical Stores. The average ASV vials and hospital stay duration were 1.23 ± 0.86 vials and 2.67 ± 1.97 days, respectively. Although the peak of snakebites occurs in April, May, and June, the demand for antivenom in April and May exceeded supply. Conclusion: The outcome of most snakebite case management was appropriate, irrespective of inadequate ASV supply in certain months. The erratic antivenom supply should be aligned with seasonal and facility-use patterns to enhance regional snakebite management.
Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise

Julien Slagboom,Jeroen Kool,Robert A. Harrison,Nicholas R. Casewell

DOI: https://doi.org/10.1111/bjh.14591

2017-02-24

British Journal of Haematology

Abstract:Snake venoms are mixtures of numerous proteinacious components that exert diverse functional activities on a variety of physiological targets. Because the toxic constituents found in venom vary from species to species, snakebite victims can present with a variety of life-threatening pathologies related to the neurotoxic, cytotoxic and haemotoxic effects of venom. Of the 1·8 million people envenomed by snakes every year, up to 125 000 die, while hundreds of thousands survive only to suffer with life-changing long-term morbidity. Consequently, snakebite is one of the world's most severe neglected tropical diseases. Many snake venoms exhibit strong haemotoxic properties by interfering with blood pressure, clotting factors and platelets, and by directly causing haemorrhage. In this review we provide an overview of the functional activities of haemotoxic venom proteins, the pathologies they cause in snakebite victims and how their exquisite selectivity and potency make them amenable for use as therapeutic and diagnostic tools relevant for human medicine.

hematology
From neglect to equity in snakebite envenoming; what the ICMR-Collaborative Centre of Excellence (CCoE) targets

Jaideep C. Menon,Bipin Nair,Sanghamitra Pati,Vijay V. Pillay,Amarendra Mahapatra,T. P. Sreekrishnan,Muralidharan Vanuopadath,Denny John,Sabarish B. Nair,Prakash K. Sahoo,Aravind M. S.,Aswathy Sreedevi,Chandrasekhar Jankiram,Joseph K. Joseph

DOI: https://doi.org/10.1371/journal.pntd.0012425

2024-09-13

PLoS Neglected Tropical Diseases

Abstract:Among the neglected tropical diseases (NTDs), which affect a fifth of the world's population and disproportionately affect underprivileged communities in the Tropics, venomous snakebite is arguably the most neglected. The World Health Organization's (WHO) list of neglected diseases (NTDs) included snakebite envenoming (SBE) in 2009. In 2013, the condition was reclassified as a neglected one, and in 2015, the WHO delisted SBE. Following a passionate plea from the late Kofi Annan, the former UN Secretary-General, representatives from Médecins Sans Frontières (MSF), the Global Snakebite Initiative (GSI), the Health Action Initiative (HAI), and other stakeholders from member countries, it was subsequently reincluded as an NTD in 2017. Notably, SBE is responsible for more deaths than all other NTDs combined [1–3]. India is disproportionately affected by SBE in terms of both incidence and mortality. Based on WHO data, it is estimated that between 1.8 and 2.7 million envenoming results from between 4.5 and 5.4 million bites worldwide each year. Out of them, 81,000 to 138,000 victims die from complications, and an additional 400,000 suffer permanent disabilities [1]. It is estimated that 58,000 victims in India die from SBE each year, which accounts for half of all deaths worldwide [4]. This is in contrast to Australia and the United States, where there are equally venomous species present but the death toll is in the single digits [5]. Males account for over 70% of SBE cases, which usually occur in the productive ages range of 20 to 60 years. The socioeconomic effects of SBE can be disastrous, particularly with the death or disability of the sole earning member of the family. In rural communities, SBE also plays a major role in the loss of livestock [6].

tropical medicine,parasitology

[Numerical taxonomy: methods and present development].

Situation of snakebite, antivenom market and access to antivenoms in ASEAN countries

Consequences of neglect: analysis of the sub-Saharan African snake antivenom market and the global context

Progress and Challenges in the Field of Snakebite Envenoming Therapeutics

Clinical management of snakebite envenoming: Future perspectives

Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?

Challenges associated with the availability, accessibility, and use of antivenoms for treating snakebite envenoming in Ghana: A MaxDiff experiment design

Therapeutic itineraries of snakebite victims and antivenom access in southern Mexico

Beyond the 'big four': Venom profiling of the medically important yet neglected Indian snakes reveals disturbing antivenom deficiencies

Snakebite Management: The Need of Reassessment, International Relations, and Effective Economic Measures to Reduce the Considerable SBE Burden

From fangs to antidotes: A scoping review on snakebite burden, species, and antivenoms in the Eastern Mediterranean Region

LED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivation.

Landscape of toxin-neutralizing therapeutics for snakebite envenoming (2015–2022): Setting the stage for an R&D agenda

Sexual behaviour and contraceptive use among socioeconomic groups of young women in the United States

Shortcomings in snake bite management in rural Cameroon: a case report

Harnessing the Cross-Neutralisation Potential of Existing Antivenoms for Mitigating the Outcomes of Snakebite in Sub-Saharan Africa

The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment

Cobra Venom: From Envenomation Syndromes to Therapeutic Innovations

Snakebites and Antisnake Venom Utilization in Ghana's Oti Region: A 6-Year Retrospective Study

Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise

From neglect to equity in snakebite envenoming; what the ICMR-Collaborative Centre of Excellence (CCoE) targets